Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.
暂无分享,去创建一个
Alain Van Dorsselaer | Alain Beck | A. van Dorsselaer | A. Beck | L. Goetsch | N. Corvaïa | Liliane Goetsch | Jean-François Haeuw | Marie-Claire Bussat | Nathalie Zorn | Virginie Robillard | Christine Klinguer-Hamour | Stéphane Chenu | Nathalie Corvaïa | C. Klinguer-Hamour | J. Haeuw | V. Robillard | M. Bussat | N. Zorn | S. Chenu | C. Klinguer‐Hamour
[1] E. Julien,et al. Residual DNA quantification in clinical batches of BBG2Na, a recombinant subunit vaccine against human respiratory syncytial virus. , 2001, Biologicals : journal of the International Association of Biological Standardization.
[2] J. L. Bailey,et al. Techniques in protein chemistry , 1989 .
[3] T. Raju,et al. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.
[4] James E. Bailey,et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.
[5] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[6] M. Trikha,et al. Monoclonal antibodies as therapeutics in oncology. , 2002, Current opinion in biotechnology.
[7] S. Tsunasawa,et al. Pyrrolidone carboxyl peptidase from the hyperthermophilic Archaeon Pyrococcus furiosus: cloning and overexpression in Escherichia coli of the gene, and its application to protein sequence analysis. , 1998, Journal of biochemistry.
[8] M. Mulkerrin,et al. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. , 1997, Journal of pharmaceutical and biomedical analysis.
[9] G. Hale,et al. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. , 2001, Cytotherapy.
[10] L. Presta,et al. Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.
[11] J. Brass,et al. Quality assurance after process changes of the production of a therapeutic antibody. , 1996, Pharmaceutica acta Helvetiae.
[12] L. Presta. Antibody engineering for therapeutics. , 2003, Current opinion in structural biology.
[13] M. Butler,et al. Comparisons of the Glycosylation of a Monoclonal Antibody Produced under Nominally Identical Cell Culture Conditions in Two Different Bioreactors , 2000, Biotechnology progress.
[14] E. Drewe,et al. Clinically useful monoclonal antibodies in treatment. , 2002, Journal of clinical pathology.
[15] R. Mhatre,et al. Strategies for locating disulfide bonds in a monoclonal antibody via mass spectrometry. , 1999, Rapid communications in mass spectrometry : RCM.
[16] L. Presta,et al. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.
[17] V. Shankar,et al. Therapeutic applications of monoclonal antibodies , 2011 .
[18] R. Dwek,et al. Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.
[19] S. Carr,et al. An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus MAb. , 1995, Analytical chemistry.
[20] Nigel Jenkins,et al. Getting the glycosylation right: Implications for the biotechnology industry , 1996, Nature Biotechnology.
[21] A. Chen,et al. Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2B8. , 1998, Journal of chromatography. A.
[22] G. Wang,et al. Variant antibody identification by peptide mapping. , 1999, Biotechnology and bioengineering.
[23] R. Huber,et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.
[24] J L Cleland,et al. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. , 1997, Journal of pharmaceutical sciences.
[25] A. Alexander,et al. Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. , 1995, Analytical chemistry.
[26] J. Bonnefoy,et al. Stability and CTL-activity of P40/ELA melanoma vaccine candidate. , 2001, Biologicals : journal of the International Association of Biological Standardization.
[27] D K Robinson,et al. Industrial choices for protein production by large-scale cell culture. , 2001, Current opinion in biotechnology.
[28] P. Carter,et al. Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.
[29] P. Roepstorff,et al. Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[30] E. Julien,et al. Stability and CTL activity of N-terminal glutamic acid containing peptides. , 2001, Journal of Peptide Research.
[31] S. Langermann,et al. Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1 , 2002, The Journal of Immunology.
[32] J. Gebler,et al. Letter: The Use of Electrospray Ionization Mass Spectrometry to Distinguish the Lot-to-Lot Heterogeneity of An Antigen Specific Monoclonal Antibody from a Specific Cellular Clone , 1999 .
[33] A. Jonsson. Mass spectrometry for protein and peptide characterisation , 2001, Cellular and Molecular Life Sciences CMLS.
[34] Inger Sandlie,et al. Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.
[35] P. T. Jones,et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.
[36] M. Jefford,et al. Rational approaches to human cancer immunotherapy , 2003, Journal of leukocyte biology.
[37] A. Chen,et al. Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. , 1996, Journal of chromatography. A.
[38] C. Beddell,et al. Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H. , 1995, Analytical chemistry.
[39] Wei Zhang,et al. Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody. , 2002, Analytical biochemistry.
[40] S. Chamow,et al. Therapeutic antibody expression technology. , 2001, Current opinion in biotechnology.
[41] J L Cleland,et al. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. , 2001, Journal of pharmaceutical sciences.
[42] A. Dickson,et al. Characterization of the stability of recombinant protein production in the GS-NS0 expression system. , 2001, Biotechnology and bioengineering.
[43] B. Kabakoff,et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[44] P. Pauwels,et al. A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts , 2005, International journal of cancer.
[45] J. Rohrer,et al. Protein variant separations using cation exchange chromatography on grafted, polymeric stationary phases , 2001, Proteomics.
[46] C. Mantzoros,et al. The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications , 2002, Oncology.
[47] Michael Butler,et al. A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. , 2002, Analytical biochemistry.
[48] F. Emmrich,et al. Purification and analytical characterization of an anti-CD4 monoclonal antibody for human therapy. , 1994, Journal of chromatography. A.
[49] L. Taylor,et al. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. , 1997, Analytical biochemistry.
[50] T. Nguyen,et al. Synthesis and characterization of Respiratory Syncytial Virus protein G related peptides containing two disulfide bridges. , 2000, The journal of peptide research : official journal of the American Peptide Society.
[51] M Vanderlaan,et al. Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes , 2001, Biotechnology & genetic engineering reviews.
[52] I. Krull,et al. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. , 1999, Analytical biochemistry.
[53] T. Nguyen,et al. Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus. , 2001, Journal of immunological methods.
[54] T. Torphy,et al. Monoclonal antibodies: boundless potential, daunting challenges , 2002 .
[55] Janice M Reichert,et al. Therapeutic monoclonal antibodies: trends in development and approval in the US. , 2002, Current opinion in molecular therapeutics.